Bronchiolitis, Viral Clinical Trial
Official title:
Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis
Respiratory tract infections caused by respiratory syncytial virus (RSV) are a worldwide burden and represent a major public health issue. In France, bronchiolitis is responsible for around 100,000 emergency room visits and 50,000 hospital admissions every year; 75% of infants hospitalised for RSV bronchiolitis are healthy full-term children. Recent discoveries concerning the specific viral epitopes of RSV have made it possible to move from an empirical approach to a targeted preventive or curative approach (monoclonal antibodies, vaccines, anti-viral drugs). Nirsevimab is a monoclonal antibody against RSV with enhanced neutralising activity and a prolonged half-life. A randomised, placebo-controlled phase III trial demonstrated the effectiveness of nirsevimab in reducing lower respiratory tract infections caused by RSV requiring medical management in healthy premature and term infants, with a favourable safety profile. The US Food and Drug Administration (FDA) approved the first RSV vaccine on May 3, 2023, and the second was approved on May 31, 2023. Nirsevimab was approved by the European Medicines Agency (EMA) on November 4, 2022.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04989114 -
Nasal Bubble Continuous Positive Airway Pressure in Reducing Respiratory Distress in Children With Bronchiolitis
|
N/A | |
| Recruiting |
NCT04287959 -
SWISH Trial (Strategies for Weaning Infants on Supportive High Flow)
|
N/A | |
| Not yet recruiting |
NCT01618175 -
Home Oxygen Treatment of Childhood Acute Bronchiolitis
|
N/A | |
| Completed |
NCT01247064 -
Hypertonic Saline for Acute Bronchiolitis
|
Phase 4 | |
| Completed |
NCT03062917 -
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
|
N/A | |
| Completed |
NCT02571517 -
Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis
|
Phase 4 | |
| Completed |
NCT02853838 -
Chest Physiotherapy in Infants Between 0 and 12 Months Old With Acute Bronchiolitis SRV(+)
|
N/A | |
| Terminated |
NCT03252119 -
High Flow Oxygen Therapy vs Standard Care in Infants With Viral Bronchiolitis
|
N/A | |
| Active, not recruiting |
NCT04740294 -
Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis
|
Phase 2/Phase 3 | |
| Terminated |
NCT03959384 -
Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
|
Phase 3 | |
| Completed |
NCT00119002 -
The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis
|
Phase 4 | |
| Terminated |
NCT04221087 -
Steroid Use in Non-RSV Bronchiolitis
|
Phase 4 | |
| Recruiting |
NCT04764929 -
Pediatric Helmet CPAP Pilot Study
|
N/A | |
| Completed |
NCT00122785 -
Single Injection of Dexamethasone for Acute Bronchiolitis in Young Children
|
N/A |